Dupixent Lawsuit Law Firm In Alabama

‍

Dupixent Lawsuits: What Alabama Patients Need to Know

If you or a loved one were prescribed Dupixent (dupilumab) and later developed a form of T-cell lymphoma, you may have the right to pursue a legal claim.

Our firm is actively investigating cases involving individuals who developed conditions such as cutaneous T-cell lymphoma (CTCL), peripheral T-cell lymphoma (PTCL), mycosis fungoides, or Sézary syndrome after using this medication.

Call (205) 322-8880 now for a free consultation. There are no upfront fees, and you pay nothing unless we recover compensation for you.

Drug manufacturers have a legal obligation to warn patients and physicians about known or reasonably knowable risks. When that does not happen, and patients suffer serious harm, legal action may be appropriate.

‍

2026 Update: Federal Litigation Developments

As of early 2026, attorneys across the country have moved to consolidate federal Dupixent-related cancer cases into multidistrict litigation (MDL). While the court has not yet made a final decision, these filings signal growing concern about the alleged connection between Dupixent and certain lymphomas.

Individuals in Alabama and across the country do not need to wait for MDL formation to take action. Filing sooner may help preserve evidence and protect your claim.

Do not wait to protect your rights. Contact our firm today at (205) 322-8880 to speak directly with our team about your potential case.

‍

What Is Dupixent?

Dupixent is a biologic medication approved by the FDA in 2017. It is commonly prescribed to treat:

• Moderate-to-severe eczema (atopic dermatitis)
• Asthma
• Chronic sinus conditions with nasal polyps
• Eosinophilic esophagitis
• Prurigo nodularis
• Chronic obstructive pulmonary disease (COPD)

While it has helped many patients manage chronic conditions, concerns have emerged about whether the drug may contribute to or mask serious underlying cancers.

‍

The Core Allegation Behind Dupixent Lawsuits

Dupixent lawsuits generally center on one issue: whether the manufacturers failed to adequately warn about a potential link between the drug and T-cell lymphomas.

Some claims allege that Dupixent may:

• Cause lymphoma in certain patients
• Accelerate the progression of an existing cancer
• Mask early symptoms of lymphoma, delaying diagnosis

Despite these concerns, current labeling has been criticized for not clearly addressing lymphoma risks.

If you were diagnosed with lymphoma after taking Dupixent, call (205) 322-8880 now. Our firm can evaluate your claim at no cost.

‍

Understanding the Types of Cancer Involved

Cutaneous T-Cell Lymphoma (CTCL)

CTCL is a rare cancer that affects the skin. It often begins with symptoms that closely resemble eczema, including:

• Red or inflamed patches
• Itchy or scaly skin
• Recurring flare-ups

Because these symptoms mimic the very condition Dupixent is designed to treat, some patients may be misdiagnosed. In these cases, treatment may suppress visible symptoms while the underlying cancer continues to progress.

Common forms of CTCL include mycosis fungoides and Sézary syndrome, which can become serious if not identified early.

Peripheral T-Cell Lymphoma (PTCL)

PTCL is a broader and often more aggressive category of lymphoma. It may involve lymph nodes and other parts of the body and typically requires intensive treatment such as chemotherapy.

‍

Why Diagnosis Can Be Delayed

One of the most concerning issues raised in these cases is the overlap between eczema and early-stage lymphoma. Patients may initially respond to treatment, reinforcing the belief that the diagnosis was correct.

However, if the underlying condition is actually lymphoma, the disease may continue to develop unnoticed. By the time it is correctly diagnosed, it may be at a more advanced stage.

This delay can have serious consequences. If something does not feel right about your diagnosis or progression, speak with our firm immediately at (205) 322-8880.

‍

Reported Warning Signs

Patients who have used Dupixent should be aware of symptoms that may warrant further medical evaluation, including:

• Skin conditions that worsen or do not respond as expected
• Persistent or unusual rashes or lesions
• Swollen lymph nodes
• Unexplained weight loss
• Night sweats or recurring fevers

These symptoms do not automatically indicate cancer, but they should be evaluated by a qualified medical professional.

‍

Scientific Research and Ongoing Investigation

Recent studies and adverse event data have raised questions about a possible association between Dupixent and T-cell lymphoma. Federal regulators have reviewed reports and continue to monitor the situation.

While research is ongoing, the growing body of evidence has contributed to increased litigation and regulatory attention.

‍

Your Legal Options

If you developed lymphoma after using Dupixent, you may be entitled to compensation for:

• Medical expenses
• Lost income
• Pain and suffering
• Long-term health impacts

Our firm handles these cases on a contingency fee basis, meaning there are no upfront costs. You only pay if compensation is recovered on your behalf.

You have nothing to lose by getting answers. Call (205) 322-8880 now for a completely free case review.

‍

Speak With Our Firm Today

At Pittman, Dutton, Hellums, Bradley & Mann, P.C., our firm represents individuals harmed by dangerous drugs and defective medical products.

We understand how overwhelming a diagnosis like lymphoma can be, especially when it may be linked to a medication you trusted. We are here to help you understand your rights and pursue the compensation you deserve.

Call (205) 322-8880 now or fill out our online contact form to get started. Free consultations.

‍